Immunotherapy of malignant melanoma using T cell-activating microbeads

Area of Science:

• Oncology
• Immunotherapy
• Nanotechnology

Background:

• Metastatic disease is a leading cause of cancer mortality, often proving difficult to treat due to widespread and aggressive tumors.
• Immune checkpoint blockers (ICBs) have improved patient outcomes by activating anti-tumor immunity, but systemic administration causes toxicities and limited responses.
• Novel local immunotherapeutic strategies are needed to enhance the treatment of metastatic cancers.

Purpose of the Study:

• To develop and evaluate antibody-functionalized paramagnetic microbeads for localized cancer immunotherapy.
• To assess the dual mechanism of direct cancer cell killing and enhanced T cell-mediated anti-tumor immunity.

Main Methods:

• Antibody-functionalized paramagnetic microbeads were engineered.
• Microbeads were tested for their ability to be engulfed by cancer cell lines and induce direct cytotoxicity.
• Microbeads loaded with anti-CD28 monoclonal antibody (BBC-28) were assessed for their effects on T cell proliferation, cytokine release, and T cell-mediated killing of melanoma cells.

Main Results:

• Microbeads were efficiently engulfed by various human cancer cell lines, inducing direct cytotoxicity.
• Bead-bound conventional anti-CD28 monoclonal antibody (BBC-28) stimulated T cell proliferation and cytokine release.
• BBC-28 enhanced the killing of melanoma cells by melanoma-reactive T cells, demonstrating a 'second hit' effect.

Conclusions:

• Antibody-functionalized paramagnetic microbeads represent a promising local immunotherapeutic approach for metastatic disease.
• BBC-28 microbeads offer a dual therapeutic strategy, combining direct tumor cell toxicity with enhanced anti-cancer T cell immunity.
• Local application of BBC-28 microbeads may provide an effective treatment for metastatic cancers, particularly melanoma.